Health Care Stocks: Check Out This Low-Cost Market Beater

These health care stocks have been growing by double digits. Should you buy?

Apr 15, 2014 at 5:15PM

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF (NYSEMKT:IYH) could save you a lot of trouble. Instead of trying to figure out which health care stocks will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. This ETF, focused on health care stocks, sports a relatively low expense ratio -- an annual fee -- of 0.46%.

The iShares US Healthcare ETF has outperformed the world market over the past five and 10 years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why health care stocks?
For starters, the world's growing and aging population will keep demand rising for health care products and services. On top of that, Obamacare is ushering more Americans into health coverage, bringing health care companies more customers -- and thereby boosting the prospects of their stocks.

More than a handful of health care stocks had strong performances over the past year. Regeneron Pharmaceuticals (NASDAQ:REGN), for example, surged 34%, partly on the success of its wet age-related macular degeneration drug, Eylea, which generated close to $2 billion in sales last year and may gain approval to tackle other eye issues, too. Regeneron's pipeline has a lot of potential, including its PCSK9 inhibitor, alirocumab, which is faring well in Japanese trials. The stock is not a slam-dunk, though, as there's able competition, and its valuation isn't exactly cheap. Regeneron reports its first-quarter results on May 8.

Biogen Idec (NASDAQ:BIIB) jumped 32%. The company is enjoying strong sales of its multiple sclerosis drug Tecfidera, while also gaining Food and Drug Administration approval for its developmental hemophilia B treatment, Alprolix. In its last quarter, earnings popped 56%, with Tecfidera sales approaching $400 million. The company's pipeline holds much promise, with additional treatments for hemophilia and MS, for example.

Gilead Sciences (NASDAQ:GILD) gained 27%. Its recently approved oral hepatitis C treatment, Sovaldi, has blockbuster potential and is off to a strong start, but many are balking at its steep price tag of around $84,000 for a 12-week course. Sales of Gilead's HIV drug Stribild are growing rapidly,  and it might achieve blockbuster status soon, too. (Gilead is a leader in HIV treatments, which generate much of its revenue.) The company's fourth quarter was strong, in large part due to new products -- which is good for a drug company, as patent expirations limit the value of older drugs. With a forward price-to-earnings ratio near 11, the stock is worth considering.

Other health care stocks didn't do quite so well over the last year but could see their fortunes change in years to come. Celgene Corporation (NASDAQ:CELG), another biotech concern, tacked on 11%. It's on a roll, thanks in part to its anemia drug, Revlimid, with many hopeful about its recently approved arthritis drug, Otezla, too. Celgene is investing heavily in other companies with promising early-stage drugs, a move that could pay off handsomely in many years, not months. As my colleague Stephen Simpson has noted, Celgene has "a deep early stage pipeline of oncology drugs" and "meaningful label expansion opportunities for approved drugs." It appears to be undervalued, too, with its forward P/E ratio near 15.

The big picture
If you're interested in adding some health care stocks to your portfolio, consider doing so via an ETF. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Selena Maranjian, whom you can follow on Twitter, owns shares of Celgene, Gilead Sciences, and Regeneron Pharmaceuticals. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers